对《三庚酸甘油酯：首次批准》的更正
Correction to: Triheptanoin: First Approval.
作者信息
Shirley Matt
机构信息
Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand.
出版信息
Drugs. 2020 Nov;80(17):1873. doi: 10.1007/s40265-020-01426-5.
Abstract
The article Triheptanoin: First Approval, written by Matt Shirley, was originally published electronically in SpringerLink on 8 September 2020 without open access. After publication in volume 80, issue 15, pages 1595-1600 Ultragenyx Pharmaceutical Inc., requested that the article be Open Choice to make the article an open access publication.
摘要
马特·雪莉所著的《三庚酸甘油酯：首次获批》一文最初于2020年9月8日以非开放获取的形式在施普林格在线平台上电子发表。在该文发表于第80卷第15期第1595 - 1600页后，Ultragenyx制药公司要求将该文转为开放选择模式，使其成为开放获取出版物。
相似文献
1
Correction to: Triheptanoin: First Approval.对《三庚酸甘油酯：首次批准》的更正
Drugs. 2020 Nov;80(17):1873. doi: 10.1007/s40265-020-01426-5.
2
Correction to: Bimatoprost Implant: First Approval.更正：比马前列素植入剂：首次批准。
Drugs Aging. 2020 Jul;37(7):549. doi: 10.1007/s40266-020-00778-7.
3
Correction to: Sarecycline: First Global Approval.对《Sarecycline：首次全球获批》的勘误
Drugs. 2019 May;79(7):795. doi: 10.1007/s40265-019-01122-z.
4
Correction to: Polatuzumab Vedotin: First Global Approval.对《泊洛妥珠单抗：首次全球获批》的更正
Drugs. 2019 Nov;79(16):1829. doi: 10.1007/s40265-019-01214-w.
5
Correction to: Revefenacin: First Global Approval.对《瑞芬太尼：首次全球获批》的更正
Drugs. 2019 Apr;79(6):689. doi: 10.1007/s40265-019-01106-z.
6
Correction to: Eculizumab: A Review in Neuromyelitis Optica Spectrum Disorder.
Drugs. 2020 May;80(7):729. doi: 10.1007/s40265-020-01315-x.
7
Correction to: GP2015: An Etanercept Biosimilar.对《GP2015：一种依那西普生物类似药》的勘误
BioDrugs. 2018 Oct;32(5):525. doi: 10.1007/s40259-018-0296-z.
8
Correction to: Satralizumab: First Approval.对《萨特利珠单抗：首次获批》的更正
Drugs. 2020 Sep;80(14):1483. doi: 10.1007/s40265-020-01391-z.
9
Correction to: Migalastat: A Review in Fabry Disease.对《米加司他：法布里病综述》的更正
Drugs. 2019 Aug;79(12):1363. doi: 10.1007/s40265-019-01166-1.
10
Correction to: Ubrogepant: First Approval.更正：ubrogepant：首次批准。
Drugs. 2020 Apr;80(5):523. doi: 10.1007/s40265-020-01292-1.
引用本文的文献
1
Heptanoic and medium branched-chain fatty acids as anaplerotic treatment for medium chain acyl-CoA dehydrogenase deficiency.庚酸和中链支链脂肪酸作为中链酰基辅酶 A 脱氢酶缺乏症的补充治疗。
Mol Genet Metab. 2023 Nov;140(3):107689. doi: 10.1016/j.ymgme.2023.107689. Epub 2023 Aug 25.
Zotero 插件